DaVita Inc.
HealthcareNYSE:DVA · New York Stock Exchange
+$5.85 today
Vol 0.53M · Avg 0.85M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-114.7%
avg 97.2%
ROIC
10.6%
avg 8.4%
ROA
4.3%
avg 3.9%
Analysis
ROIC is currently the strongest return metric at 10.6% versus its period average of 8.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Javier J. Rodriguez | Chief Executive Officer & Executive Director | $4.07M | — | 55 | $7,813.00 | 0.01% |
David Maughan | Chief Operating Officer of DaVita Kidney Care | $1.66M | — | 49 | $94,105.00 | 0.15% |
Joel Ackerman | Chief Financial Officer & Treasurer | $1.63M | — | 61 | $132,434.00 | 0.21% |
Kathleen Alyce Waters | Chief Legal & Public Affairs Officer | $1.43M | — | 58 | $158,462.00 | 0.25% |
James O. Hearty | Chief Compliance Officer | $1.07M | — | 57 | $22,389.00 | 0.03% |
Partha Das | Chief Medical Officer of DaVita International | — | — | — | — | — |
Christopher Michael Berry | Group Vice President & Chief Accounting Officer | — | — | 51 | $19,640.00 | 0.03% |
Jeffrey Allen Giullian | Chief Medical Officer of Kidney Care | — | — | — | — | — |
Stephanie Hendrickson | Chief People Officer | — | — | — | — | — |
Madhu Narasimhan | Chief Information Officer | — | — | — | — | — |
Nic Eliason | Group Vice President of Investor Relations | — | — | — | — | — |
Misha Palecek | Chief Transformation Officer of U.S. Kidney Care Business | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$684.80M
Net Sentiment
$684.80M
Net selling
Most Active
BERKSHIRE HATHAWAY INC
4 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 10 sells worth $684.80M over the last 12 months. That adds up to net selling of $684.80M. BERKSHIRE HATHAWAY INC was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -23.0% | +21.0% (14yr)1 analysts |
| Revenue | N/A | N/A | +19.0% | +1.0% (14yr)2 analysts |
| Net Income | N/A | N/A | -20.5% | +13.5% (14yr)2 analysts |
| EBIT | N/A | N/A | -4.3% | +4.9% (14yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +19.0% over three years. Forward estimates point to EPS at +21.0% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$32.70B
Align Technology, Inc.
NASDAQ:ALGN
$12.50B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.84B
Molina Healthcare, Inc.
NYSE:MOH
$10.43B
Henry Schein, Inc.
NASDAQ:HSIC
$9.30B
Universal Health Services, Inc.
NYSE:UHS
$9.19B
The Ensign Group, Inc.
NASDAQ:ENSG
$8.68B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.71B
AptarGroup, Inc.
NYSE:ATR
$7.53B
Chemed Corporation
NYSE:CHE
$5.57B
Who manages DVA?
DaVita Inc. (DVA) lists 12 active executives. The top listed executive is Partha Das, Chief Medical Officer of DaVita International.
Are DVA insiders buying or selling?
Recent insider activity shows net selling of $1.07B.
Explore More
Continue the stock analysis
Jump to another research area for this company.